TesamorelinTesamorelin est un analogue d'hormones de libération d'hormone de croissance qui a été démontré pour augmenter les niveaux de LGF-1 chez les hommes par une moyenne de 181 microgrammes / litre. LT se lie et stimule les récepteurs de GHRH humains avec une puissance similaire à celle du GHRH endogène. LT a AHOST d'autres avantages, y compris les effets nootropes et la réduction des triglycérides. Il a ensuite été démontré que TesamorelinResearch diminue l'épaisseur de milieux intima carotide (CLMT), le tissu adipeux viscéral (TVA) et les protéines C-réactives (CRP) dans une étude récente. Il n'a pas été démontré que cela affecte de manière significative d'autres hormones hypophysaires et leurs mécanismes respectifs dans le corps. De plus, des études ont montré qu'il améliore la fonction cognitive pour les personnes âgées en bonne santé et également pour les personnes souffrant de troubles cognitifs légers qui courent un risque de progression vers la maladie d'Alzheimer.IpamorinelinIpamorelin is a selective GH-Secretagogue and ghrelin receptor agonist. The potency ofghrelin stimulation can be compared to GHRP6 with less appetite stimulation properties.However, unlike other GH-Secretagogues this pentapeptide doesn’t release the samevolumes of cortisol, acetylcholine, prolactin and aldosterone. lt is for this reasonlpamorelin has been considered the first selective GH-Secretagogue.
By combining both ipamorelin and tesamorelin, it may be possible to produce enhancedeffects because each peptide stimulates the growth hormone axis via two different mechanisms. Together, they both work synergistically to stimulate the pituitary gland toproduce and secrete your own natural arowth hormone at more vouthful levels, Researchhas shown that the net effect of combining both of these peptides results in better deepsleep, reduced triglycerides, VAT, and clMT, improved cognition, and overall bettermetabolic function.
lpamorelin and Tesamorelin exhibits minimal side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale tohumans. lpamorelin and Tesamorelin are for sale at PEPTIDE GURUS is limited toeducational and scientific research only, not for human consumption. Only buy lpamorelinand Tesamorelin if you are a licensed researcher.Article auteurLa littérature ci-dessus a été étudiée, édité et organisée par le Dr E. Logan, M.D. Le Dr Elogan est titulaire d'un doctorat de la Case Western Reserve University School ofmedicine et d'un B.S. en biologie moléculaire.Journa-autheurt scientifiqueDavid E. Beck, MD, co-author of“Prospective, randomized, controlled, proof-of-conceptstudy of the Ghrelin mimetic ipamorelin for the management of postoperative ileus inbowel resection patients” specializes in colon and rectal surgery.
David E. Beck, MD is being referenced as one of the leading scientists involved in there search and development of lpamorelin. In no way is this doctor/scientist endorsing oradvocating the purchase, sale, or use of this product for any reason. There is no affiliationor relationship, implied or otherwise, between PEPTIDE GURUS and this doctor. Thepurpose of citing the doctor is to acknowledge, recognize, and credit the exhaustiveresearch and development efforts conducted by the scientists studying this peptide. DavidE. Beck, MD is listed in [4 ]under the referenced citations.Critations référencées1.Adrian, S., et al. (2019).The Growth Hormone Releasing Hormone Analogue,Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIVJ Frailty Aging, 8(3):154-159.DO1: 10.14283/jfa.2018.45.
2.Clemmons, D.R., Miller, S.,& Mamputu, J.(2017). Safety and Metabolic Effects ofTesamorelin, A Growth Hormone-releasing Factor Analogue, in Patients with Type2 Diabetes: A Randomized, Placebo-controlled Trial. PLoS One, 12(6):e0179538DOl:10.1371/journal.pone.0179538.
3.Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M,Orskov H.lpamorelin, a new growth-hormone-releasing peptide, induceslongitudinal bone growth in rats. Growth Horm IGF Res. 1999 Apr;9(2):106-13. doi.10.1054/ghir.1999.9998.PMID: 10373343.
4.Beck, David E., et al. “Prospective, Randomized, Controlled, Proof-of-ConceptStudy of the Ghrelin Mimetic lpamorelin for the Management of Postoperative lleusin Bowel Resection Patients.” International Journal ofColorectal Disease, vol. 29no.12,21 0ct.2014,pp.1527-1534,10.1007/s00384-014-2030-8
5.Michael Ankersen, Nils L. Johansen, Kjeld Madsen, Birgit S. Hansen, KirstenRaun, Karin Kramer Nielsen, Henning Thggersen, Thomas K. Hansen, BerndPeschke, Jesper Lau, Behrend F. Lundt, and Peter H. Andersen. A New Series ofHighly Potent Growth Hormone-Releasing Peptides Derived fromlpamorelin.Journal of Medicinal Chemistry 1998 41 (19),3699-3704. DO1:10.1021/im9801962.
6.Raun, Kirsten & Hansen, B & Johansen, N & Thøgersen, Henning & Madsen, K &Ankersen, Michael & Hongaard Andersen, Peter. (1998). lpamorelin, the firstselective growth hormone secretagogue.European journal of endocrinology /European Federation of Endocrine Societies.139.552-61.10.1530/eje.0.1390552.
7.Fourman, L.T., et al. (2017). Visceral Fat Reduction with Tesamorelin is Associatedwith lmproved Liver Enzymes in HIV. AIDS, 31(16):2253-2259.DO1:10.1097/0AD.0000000000001614.
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE AREFOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies(Latin: in glass) are performed outside of the body. These products are not medicines ordrugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals isstrictly forbidden by law.
